A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT02272777 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Imatinib
DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals